This letter refutes the “overdiagnosis” narrative, blaming the stimulant shortage on DEA regulatory failures, clinical constraints, and recognition of historical underdiagnosis. By concluding that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results